Landmark MMRF CoMMpass
Study reaches major milestone
SM
1,000 PATIENTS
T H E MMR F I S G R ATE F U L TO
T H E 1 , 0 0 0 PAT I E N T S W H O S E
PA RT I C I PAT I ON W I L L H E L P
U S I M PROVE T R E ATM E N T S
A N D FI N D C U R E S .
In September, the MMRF announced that the landmark MMRF
CoMMpass Study,SM the largest long-term genomic study ever conducted
in myeloma, reached a major milestone with full enrollment — an unprecedented 1,000 patients participating. To put this in perspective, in relative
terms 1,000 patients with multiple myeloma is the equivalent of more than
1.2 million patients with type 2 diabetes.
The global study is mapping the genomic profile of each enrolled patient
in order to advance our understanding of disease progression, including
patient response to therapies. Tissue samples will be genetically analyzed
when the patient is first diagnosed, and then each time there is a change in
treatment, over the course of eight years.
Data from the study will improve our understanding of the disease biology at
diagnosis, and how it changes in response to various treatment interventions —
helping us to better anticipate optimal treatment strategies. It will also be
possible to use future MMRF CoMMpass Study data to identify and validate
the unique disease drivers of myeloma, and improve our ability to predict
these drivers for individual patients. This understanding will help improve
treatment interventions and clinical outcomes. Additionally, these data may
help us to further understand the incidence and outcomes among patients
from unique populations, such as African Americans.
FOLLOW OUR LIVE BLOG FROM ASH, DEC. 5-8, FOR THE
LATEST COMMPASS DATA ANALYSIS. themmrf.org/ash